Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2

Chen,Ying‑Ju; Chen,Shiuan‑Yin; Lovel,Ronald; Ku,Yi‑Chu; Lai,Yi‑Hui; Hung,Chiao‑Ling; Li,Yu‑Fen; Lu,Yin‑Che; Tai,Chien‑Kuo

doi:10.3892/ol.2016.4883

Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2

Authors:
- Ying‑Ju Chen
- Shiuan‑Yin Chen
- Ronald Lovel
- Yi‑Chu Ku
- Yi‑Hui Lai
- Chiao‑Ling Hung
- Yu‑Fen Li
- Yin‑Che Lu
- Chien‑Kuo Tai
View Affiliations

Affiliations: Department of Life Science and Institutes of Molecular Biology and Biomedical Science, National Chung Cheng University, Chia‑Yi 62102, Taiwan, R.O.C., Institute of Biostatistics, China Medical University, Taichung 40402, Taiwan, R.O.C.
Published online on: July 20, 2016 https://doi.org/10.3892/ol.2016.4883
Pages: 2107-2114

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral cancer is the eighth most common type of cancer among men worldwide, with an age-standardized rate of 6.3 per 100,000, and is the fourth leading cause of cancer‑associated mortality among men in Taiwan. Cisplatin and 5-fluorouracil (5-FU) are two of the most frequently utilized chemotherapy drugs for the treatment of oral cancer. Although oral cancer patients initially benefit from chemotherapy with these drugs, they may develop resistance to them, which worsens their prognosis and reduces survival rates. It has been reported that increased levels of epidermal growth factor receptor (EGFR) and multidrug resistance‑associated protein 2 (MRP2) induce drug resistance in numerous types of human cancer. Therefore, the present study employed lentivirus vector‑mediated RNA interference (RNAi) in order to target the genes encoding EGFR and MRP2 in the oral squamous cell carcinoma cell line OC2. It was observed that RNAi-mediated downregulation of EGFR or MRP2 increased the sensitivity to 5‑FU and cisplatin in OC2 cells. Downregulation of EGFR resulted in significant suppression of OC2 tumor growth following 5‑FU administration. However, simultaneous downregulation of the two genes did not further suppress the tumor growth, indicating that MRP2 does not have a significant role in the chemosensitivity of EGFR‑downregulated cells to 5‑FU. In contrast, downregulation of MRP2 was demonstrated to significantly enhance the therapeutic effects of cisplatin in EGFR‑downregulated OC2 tumors. The observation that the expression of MRP2 was positively correlated with the level of cisplatin resistance in cells suggests that RNAi‑mediated downregulation of MRP2 may be applicable as a therapeutic approach toward reversing MRP2-dependent cisplatin resistance in oral cancer.

View Figures

View References

1	Petersen PE: Strengthening the prevention of oral cancer: The WHO perspective. Community Dent Oral Epidemiol. 33:397–399. 2005. View Article : Google Scholar : PubMed/NCBI
2	de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M and Curado MP: Oral cavity cancer in developed and in developing countries: Population-based incidence. Head Neck. 32:357–367. 2010.PubMed/NCBI
3	2009 Statistics of Causes of Death. Ministry of Health and Welfare. Taipei, Taiwan: 2010.
4	Chabner BA and Roberts TG Jr: Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 5:65–72. 2005. View Article : Google Scholar : PubMed/NCBI
5	Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K and Mouratidou D: 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol. 39:380–385. 2003. View Article : Google Scholar : PubMed/NCBI
6	Ramos P and Bentires-Alj M: Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance. Oncogene. 34:3617–3626. 2015. View Article : Google Scholar : PubMed/NCBI
7	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
8	Dean M, Rzhetsky A and Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
9	Stavrovskaya AA and Stromskaya TP: Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc). 73:592–604. 2008. View Article : Google Scholar : PubMed/NCBI
10	Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M and Lage H: ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res. 12:7149–7158. 2006. View Article : Google Scholar : PubMed/NCBI
11	Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 48:495–535. 2008. View Article : Google Scholar : PubMed/NCBI
12	Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M and Doki Y: Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer. 104:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:3537–3547. 1997.PubMed/NCBI
14	Guminski AD, Balleine RL, Chiew YE, Webster LR, Tapner M, Farrell GC, Harnett PR and Defazio A: MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol. 100:239–246. 2006. View Article : Google Scholar : PubMed/NCBI
15	Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:4124–4129. 1996.PubMed/NCBI
16	Materna V, Stege A, Surowiak P, Priebsch A and Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun. 348:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
17	Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB and Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 6:552008. View Article : Google Scholar : PubMed/NCBI
18	Minegaki T, Takara K, Hamaguchi R, Tsujimoto M and Nishiguchi K: Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett. 5:427–434. 2013.PubMed/NCBI
19	Agulnik M: New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 29:2481–2491. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol. 33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
21	Chong CR and Jänne PA: The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 19:1389–1400. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhang M, Zhang X, Bai CX, Song XR, Chen J, Gao L, Hu J, Hong QY, West MJ and Wei MQ: Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer. Genet Vaccines Ther. 3:52005. View Article : Google Scholar : PubMed/NCBI
23	Wong DY, Chang KW, Chen CF and Chang RC: Characterization of two new cell lines derived from oral cavity human squamous cell carcinomas - OC1 and OC2. J Oral Maxillofac Surg. 48:385–390. 1990. View Article : Google Scholar : PubMed/NCBI
24	Lai YH, He RY, Chou JL, Chan MW, Li YF and Tai CK: Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma. J Transl Med. 12:2372014. View Article : Google Scholar : PubMed/NCBI
25	Shichinohe T, Bochner BH, Mizutani K, Nishida M, Hegerich-Gilliam S, Naldini L and Kasahara N: Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther. 8:879–889. 2001. View Article : Google Scholar : PubMed/NCBI
26	Shintani S, Li C, Mihara M, Nakashiro K and Hamakawa H: Gefitinib (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett. 201:149–155. 2003. View Article : Google Scholar : PubMed/NCBI
27	Takaoka S, Iwase M, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M, Nagumo M and Shintani S: Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells. Int J Oncol. 30:1469–1476. 2007.PubMed/NCBI
28	Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K and Hamakawa H: Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer. 107:1030–1037. 2003. View Article : Google Scholar : PubMed/NCBI
29	Shintani S, Li C, Mihara M, Yano J, Terakado N, Nakashiro K and Hamakawa H: Gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 40:43–51. 2004. View Article : Google Scholar : PubMed/NCBI
30	Lee EJ, Whang JH, Jeon NK and Kim J: The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Ann N Y Acad Sci. 1095:113–128. 2007. View Article : Google Scholar : PubMed/NCBI
31	Dai W, Li Y, Zhou Q, Xu Z, Sun C, Tan X and Lu L: Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor. J Oral Pathol Med. 43:250–257. 2014. View Article : Google Scholar : PubMed/NCBI
32	Qian M, Qian D, Jing H, Li Y, Ma C and Zhou Y: Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 32:1681–1688. 2014.PubMed/NCBI
33	Ohnishi Y, Minamino Y, Kakudo K and Nozaki M: Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency. Oncol Rep. 32:780–786. 2014.PubMed/NCBI
34	Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG and Li Y: Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 15:1981–2039. 2008. View Article : Google Scholar : PubMed/NCBI
35	Falasca M and Linton KJ: Investigational ABC transporter inhibitors. Expert Opin Investig Drugs. 21:657–666. 2012. View Article : Google Scholar : PubMed/NCBI
36	Yu M, Ocana A and Tannock IF: Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: Why has it failed to provide clinical benefit? Cancer Metastasis Rev. 32:211–227. 2013. View Article : Google Scholar : PubMed/NCBI